Search results for "Delivery"

showing 10 items of 1271 documents

An update on the xenograft and mouse models suitable for investigating new therapeutic compounds for the treatment of B-cell malignancies

2008

B-cell malignancies account for over the 90% of all lymphoid neoplasms. The clonal proliferations of B-cells show a high degree of variation in terms of clinical and presenting features, histopathology, immuophenotype, and genetics. Primary tumor samples are useful for examining the characteristics of a patients own tumor, although both primary leukemic cells and cell lines provide an initial step for screening novel compounds for their activity in some hematological malignancies, they should be followed by models in intact animals. In this review, we try to summarize the animal models generated to study B-cell malignancies, in particular, B-cell lymphoma, B-cell CLL and MM that represent t…

Lymphoma B-Cellmedicine.medical_treatmentChronic lymphocytic leukemiaAntineoplastic AgentsTargeted therapyNOAntineoplastic AgentB-cell malignanciesMiceDrug Delivery SystemsStromaSpecies SpecificityDrug DiscoverymedicineAnimalsHumansB-cell lymphomaMultiple myelomaB-cell malignancies; transgenic models; multiple myelomaPharmacologybusiness.industryAnimalCancerNeoplasms Experimentalmedicine.diseasePrimary tumorLeukemia Lymphocytic Chronic B-CellXenograft Model Antitumor AssaysLymphomamultiple myelomatransgenic modelImmunologyCancer researchB-cell malignanciebusinesstransgenic modelsDrug Delivery SystemHuman
researchProduct

Targeted oligonucleotide delivery in human lymphoma cell lines using a polyethyleneimine based immunopolyplex.

2002

The efficacy of antisense gene therapy depends on efficient delivery of oligonucleotides into targeted cells. Although polyethyleneimine based polyplexes have been reported as good transfection reagents, they are inefficient in lymphoid cell transfection. We report the construction of an immunopolyplex, a targeted nonviral vector based on a polyplex backbone and its application for oligonucleotide transfer on human lymphoma cell lines. The salient characteristic of immunopolyplex lies in the possibility of easily replacing the targeting element (antibody), leaving the polyplex backbone intact. Furthermore, a study was made of the influence of endocytosis inhibitors on immunopolyplex activit…

LymphomaOligonucleotidemedia_common.quotation_subjectEndocytic cycleGenetic VectorsOligonucleotidesPharmaceutical ScienceTransfectionBiologyEndocytosisJurkat cellsMolecular biologyIn vitroDrug Delivery SystemsCell cultureTumor Cells CulturedHumansPolyethyleneimineInternalizationmedia_commonJournal of controlled release : official journal of the Controlled Release Society
researchProduct

New Potential Therapeutic Approach for the Treatment of B-Cell Malignancies Using Chlorambucil/Hydroxychloroquine-Loaded Anti-CD20 Nanoparticles

2013

Current B-cell disorder treatments take advantage of dose-intensive chemotherapy regimens and immunotherapy via use of monoclonal antibodies. Unfortunately, they may lead to insufficient tumor distribution of therapeutic agents, and often cause adverse effects on patients. In this contribution, we propose a novel therapeutic approach in which relatively high doses of Hydroxychloroquine and Chlorambucil were loaded into biodegradable nanoparticles coated with an anti-CD20 antibody. We demonstrate their ability to effectively target and internalize in tumor B-cells. Moreover, these nanoparticles were able to kill not only p53 mutated/deleted lymphoma cell lines expressing a low amount of CD20…

Lymphomamedicine.medical_treatmentlcsh:MedicineApoptosisnanoparticles; Targeting strategies; LymphomaAggressive lymphomaMice SCIDPharmacologyAntibodies Monoclonal Murine-DerivedMiceDrug Delivery Systems0302 clinical medicineimmune system diseaseshemic and lymphatic diseasesNANOPARTICLESMedicinelcsh:ScienceCD200303 health sciencesMultidisciplinarybiologyNANOPARTICLES; ANTI-CD20; B-CELL MALIGNANCIESnanoparticleANTI-CD20Flow CytometryImmunohistochemistry3. Good healthDrug CombinationsLeukemia030220 oncology & carcinogenesisMonoclonalTargeting strategieFemaleRituximabRituximabHydroxychloroquineResearch Articlemedicine.drugLymphoma B-CellCell Survival03 medical and health sciencesMicroscopy Electron TransmissionAutophagyB-CELL MALIGNANCIESAnimalsTargeting strategies030304 developmental biologyChlorambucilbusiness.industrylcsh:RHydroxychloroquineImmunotherapyAntigens CD20medicine.diseaseDisease Models Animalbiology.proteinChlorambucillcsh:QbusinessPLoS ONE
researchProduct

Multifunctional Poly(ethylene glycol)s

2011

In the rapidly evolving multidisciplinary field of polymer therapeutics, tailored polymer structures represent the key constituent to explore and harvest the potential of bioactive macromolecular hybrid structures. In light of the recent developments for anticancer drug conjugates, multifunctional polymers are becoming ever more relevant as drug carriers. However, the potentially best suited polymer, poly(ethylene glycol) (PEG), is unfavorable owing to its limited functionality. Therefore, multifunctional linear copolymers (mf-PEGs) based on ethylene oxide (EO) and appropriate epoxide comonomers are attracting increased attention. Precisely engineered via living anionic polymerization and d…

LymphomapolyethersNanotechnologyAntineoplastic AgentsPolyethylene glycolMolecular-WeightCatalysisPolyethylene Glycolschemistry.chemical_compoundepoxidesCopolymerOrganic chemistryAnimalsLiving anionic polymerizationchemistry.chemical_classificationWeight Hyperbranched PolyglycerolsDrug CarriersDrug-Delivery SystemsEthylene oxidepoly(ethylene glycol)Ethylene-OxideGene Transfer TechniquesPolymer TherapeuticsGeneral ChemistryPolymermultivalencybioconjugatesPendant Amino-GroupsPolyethylene-GlycolchemistryPolymerizationAnionic Peg DerivativesDoxorubicinBlock-CopolymersCisplatinIn-VivoDrug carrierPeptidesEthylene glycol
researchProduct

Biodegradable Protein Nanocontainers

2015

The application of synthetic polymers for drug delivery often requires tremendous efforts to ensure biocompatibility and -degradation. To use the body's own substances can help to overcome these problems. Herein, we present the first synthesis of nanocontainers entirely composed of albumin proteins. These protein nanocontainers (PNCs) were loaded with hydrophilic compounds and release of the payload is triggered through natural lysis in vitro in human monocyte-derived dendritic cells (moDCs). No aggregation of PNCs in human blood plasma was observed, indicating stability for blood circulation. As the PNCs were readily taken up by moDCs, they are considered as a promising delivery platform f…

LysisPolymers and PlasticsBiocompatibilityHuman bloodProtein StabilityChemistryAlbuminBioengineeringNanotechnologyDendritic CellsBiomaterialsNanocapsulesAlbuminsDelayed-Action PreparationsBlood circulationProteolysisDrug deliveryMaterials ChemistryHumansHydrophobic and Hydrophilic InteractionsCells CulturedFluorescent DyesBiomacromolecules
researchProduct

Extracellular vesicles provide a capsid-free vector for oncolytic adenoviral DNA delivery

2020

Extracellular vesicles (EVs) have been showcased as auspicious candidates for delivering therapeutic cargo, including oncolytic viruses for cancer treatment. Delivery of oncolytic viruses in EVs could provide considerable advantages, hiding the viruses from the immune system and providing alternative entry pathways into cancer cells. Here we describe the formation and viral cargo of EVs secreted by cancer cells infected with an oncolytic adenovirus (IEVs, infected cell-derived EVs) as a function of time after infection. IEVs were secreted already before the lytic release of virions and their structure resembled normally secreted EVs, suggesting that they were not just apoptotic fragments of…

MECHANISM0301 basic medicineOncolytic adenovirusHistologyadenoviruHEPATITIS-B-VIRUSGenetic enhancementvirusesTETRASPANINGene deliveryBiologysolukalvotGENE DELIVERYPATHWAY03 medical and health sciences0302 clinical medicineImmune systemlcsh:QH573-671MICROVESICLESEXOSOMESsyöpähoidotlcsh:CytologyMICROPARTICLESadenoviruksetCell BiologyadenovirusExtracellular vesiclesVirologyMicrovesicles3. Good healthOncolytic virus030104 developmental biologyLytic cycle030220 oncology & carcinogenesisCELLSCancer cellonkolyyttiset virukset1182 Biochemistry cell and molecular biologycancer therapyAUTOPHAGYonkolyyttinen virushoitoextracellular vesiclesResearch ArticleDNA delivery
researchProduct

TRAIL in cancer therapy: present and future challenges.

2007

International audience; Since its identification in 1995, TNF-related apoptosis-inducing ligand (TRAIL) has sparked growing interest in oncology due to its reported ability to selectively trigger cancer cell death. In contrast to other members of the TNF superfamily, TRAIL administration in vivo is safe. The relative absence of toxic side effects of this naturally occurring cytokine, in addition to its antitumoural properties, has led to its preclinical evaluation. However, despite intensive investigations, little is known in regards to the mechanisms underlying TRAIL selectivity or efficiency. An appropriate understanding of its physiological relevance, and of the mechanisms controlling ca…

MESH: Signal Transductionmedicine.medical_treatmentClinical BiochemistryApoptosisTRAILTNF-Related Apoptosis-Inducing LigandBioinformaticsTNF-Related Apoptosis-Inducing LigandMESH : TNF-Related Apoptosis-Inducing Ligand0302 clinical medicineDrug Delivery SystemsNeoplasmsDrug DiscoveryMESH: AnimalsMESH: Neoplasms0303 health sciencesTnf superfamily3. Good healthMESH : Antineoplastic AgentsCytokine030220 oncology & carcinogenesisMolecular MedicineMESH : Drug Delivery SystemsTRAIL-Receptors.Signal transductionMESH: TNF-Related Apoptosis-Inducing LigandSignal TransductionMESH: ForecastingProgrammed cell deathMESH: Drug Delivery SystemsCancer therapyAntineoplastic AgentsArticleresistance03 medical and health sciencesmedicine[SDV.BBM] Life Sciences [q-bio]/Biochemistry Molecular BiologyAnimalsHumanscancer[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyMESH : ForecastingTRAIL-receptor agonistic antibodies[ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular Biology030304 developmental biologyPharmacologyMESH : Signal TransductionMESH: Humansbusiness.industryMESH: ApoptosisMESH : HumansCancermedicine.diseaseMESH : NeoplasmsCancer cellImmunologyMESH: Antineoplastic AgentsMESH : AnimalsbusinessTRAIL-ReceptorsMESH : ApoptosisForecasting
researchProduct

INULIN GRAFT CO-POLYMERS AS SELF-ASSEMBLING MICELLES FOR DRUG DELIVERY

2014

MICELLESDRUG DELIVERYINULININULIN MICELLES DRUG DELIVERYINULIN; MICELLES; DRUG DELIVERY
researchProduct

PRODUCTION VIA MICROFLUIDICS OF FIBRILLAR AND NANOMETRIC BIOMATERIALS FOR REGENERATIVE MEDICINE AND DRUG DELIVERY POURPOSES

2019

Microfluidic technique offers mild operating conditions suitable for fabrication of fibers and cell encapsulation and can be applied for controlled production of nanometric biomaterials1 . Ionotropic polysaccharides are routinely employed for microfluidics. To be processed, nonionotropic polysaccharides, such as Hyaluronic Acid (HA), should be chemically crosslinked during fabrication2 . In order to avoid chemical crosslinking, we designed an ionic strenght sensible HA derivative suitable for microfluidics2 . Here we describe the use of such HA derivative for fabrication of fibrillar and nanometric biomaterials for regenerative medicine and drug delivery applications. For muscle tissue rege…

MICROFLUIDICS BIOMATERIALS REGENERATIVE MEDICINE DRUG DELIVERY
researchProduct

Macromolecular Prodrugs Based on Synthetic Polyaminoacids: Drug Delivery and Drug Targeting in Antitumor Therapy

2011

In the last twenty years a depth study on potential pharmaceutical applications of synthetic polymers at proteinlike structure as carrier for macromolecular prodrug production has been performed in academia and in industry. In particular α,β-poly(N-2-hydroxyethyl)-DL-aspartamide (PHEA), α,β-polyaspartylhydrazide (PAHy), poly(glutamic acid) (PGA), poly(aspartic acid) (PAA) and polylysine (PLL) have been extensively studied in this field. In the present review, the use of PHEA, PAHy, PGA as starting materials to prepare macromolecular prodrugs is reported and drug delivery and targeting aspects have been considered.

Macromolecular prodrugsStereochemistryMacromolecular SubstancesAntineoplastic AgentsGeneral MedicineGlutamic acidCombinatorial chemistryAntitumor therapyαβ-poly(N-2-hydroxyethyl)-DL-aspartamideαβ-polyaspartylhydrazide poly(glutamic acid) carrierchemistry.chemical_compoundanticancer drugsDrug Delivery SystemschemistryTargeted drug deliverySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoPolylysineDrug DiscoveryAspartic acidDrug deliveryAnimalsHumansProdrugsAmino Acids
researchProduct